Inaugural BioPharmaceutical Royalty Rates and Deal Terms Survey

2008 Survey Highlights

• Over 150 deals analyzed, involving pharmaceutical companies (28%), biotechnology companies (26%), and academic Institutions (35%).
• 120 deals completed in 2006 or 2007
• Key Deal Terms
• Small Molecule compounds were included in more than 50% of all deals submitted
• 88% of deals were exclusive
• 54% of deals included a fixed royalty; 33% included tiered royalty rates
• 80% included an upfront payment
• 90% of deals included U.S. rights; 70% were worldwide
• 57% of products covered have estimated peak sales of less than $100M